Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Physiol Res ; 63(2): 189-97, 2014.
Article in English | MEDLINE | ID: mdl-24397805

ABSTRACT

Atorvastatin and insulin have distinct mechanisms of action to improve endothelial function. Therefore, we hypothesized that atorvastatin and insulin therapies alone or in combination could have beneficial effects on endothelium-dependent vascular reactivity, oxidative stress, inflammation and metabolic parameters in Goto-Kakizaki (GK) rats, a model of type 2 diabetes fed with atherogenic diet (GKAD). In parallel with the development of diabetes and lipid profile, the generation of oxidative stress was determined by measurement of lipid peroxides and oxidized proteins and the presence of inflammation was evaluated by assessing C-reactive protein (CRP). Additionally, endothelial dependent and independent vascular sensitivity to acetylcholine and sodium nitroprusside were evaluated. GKAD showed increased carbonyl stress, inflammation, fasting glycemia, dyslipidemia and endothelial dysfunction when compared to control GK rats. Noteworthy, supplementation with insulin deteriorated endothelial dysfunction while atorvastatin induced an improvement. Atorvastatin and insulin therapies in combination improved metabolic parameters, CRP levels and insulin resistance indexes and ameliorated endothelial dysfunction in GKAD rats while they were unable to reduce urinary 8-isoprostranes and plasma carbonyl compounds. The therapeutic association of atorvastatin and insulin provided a better metabolic control with a reduction in endothelial dysfunction in GKAD rats by a mechanism that involves an improvement in systemic inflammation.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Endothelium, Vascular/drug effects , Heptanoic Acids/administration & dosage , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Pyrroles/administration & dosage , Animals , Atorvastatin , Blood Glucose/drug effects , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/physiopathology , Dose-Response Relationship, Drug , Drug Therapy, Combination , Endothelium, Vascular/physiopathology , Male , Rats , Treatment Outcome
2.
Diabetes Metab Res Rev ; 27(1): 54-62, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21218508

ABSTRACT

BACKGROUND: non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress. However, the pathophysiology of NAFLD in type 2 diabetes with hyperlipidaemia is not fully known, as well as the utility of the commonly prescribed anti-diabetic and lipid-lowering drugs in ameliorating liver injury markers. METHODS: hepatic complications of type 2 diabetes with hyperlipidaemia and the effects of atorvastatin and metformin, isolated and in association, in systemic and hepatic inflammatory and oxidative stress markers were tested using genetic type 2 diabetic Goto-Kakizaki rats fed with a high-fat diet. RESULTS: the high-fat diet aggravated the overall metabolic state and the hepatic markers of injury. All treatments decreased fasting glycaemia, insulin resistance and free fatty acid levels. Combined treatment further decreased C-reactive protein (CRP), adiponectin, liver tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), systemic and hepatic oxidative stress and portal inflammation. CONCLUSIONS: our data provides evidence of a greater benefit with a combination of atorvastatin and metformin in improving liver injury in type 2 diabetes with hyperlipidaemia.


Subject(s)
Diabetes Complications/drug therapy , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Heptanoic Acids/pharmacology , Hyperlipidemias/drug therapy , Metformin/pharmacology , Pyrroles/pharmacology , Animals , Anticholesteremic Agents/pharmacology , Atorvastatin , Body Weight/drug effects , C-Reactive Protein/metabolism , Drug Combinations , Fatty Liver/prevention & control , Hyperlipidemias/complications , Hypoglycemic Agents/pharmacology , Insulin Resistance , Interleukin-6/metabolism , Liver/cytology , Liver/drug effects , Liver/metabolism , Non-alcoholic Fatty Liver Disease , Oxidative Stress/drug effects , Rats , Rats, Inbred Strains , Tumor Necrosis Factor-alpha/metabolism
3.
J Food Sci ; 74(1): H8-H14, 2009.
Article in English | MEDLINE | ID: mdl-19200099

ABSTRACT

The present study was aimed to evaluate the effect of food deprivation in brain oxidative status of Wistar and Goto-Kakizaki (GK) rats. For this purpose, we evaluated several oxidative stress parameters: lipid peroxidation (thiobarbituric acid reactive substances [TBARS]) and protein oxidation markers, hydrogen peroxide (H(2)O(2)) levels, nonenzymatic (reduced [GSH] and oxidized glutathione [GSSG] and vitamin E) and enzymatic (glutathione peroxidase [GPx], glutathione reductase [GRed], and manganese superoxide dismutase [MnSOD]) antioxidant defenses. Four-mo-old Wistar and GK rats were divided into 2 groups. One group of each rat strain was maintained under normal diet and the other groups were maintained under 50% food deprivation during 2 mo. GK rats under normal diet presented lower levels of vitamin E and higher GRed activity and GSH/GSSG ratio when compared with Wistar control rats. In Wistar rats, food deprivation induced a significant decrease in vitamin E levels and a significant increase in GPx activity, H(2)O(2) production, and TBARS formation in the presence of the prooxidant pair ADP/Fe(2+). However, GK rats under food deprivation presented a significant decrease in vitamin E levels and GRed activity and a significant increase in H(2)O(2) production when compared with GK under normal diet. In summary, our results indicate that food deprivation affects brain oxidative status, which could predispose brain cells to degeneration and death.


Subject(s)
Brain/metabolism , Food Deprivation , Glutathione/metabolism , Hydrogen Peroxide/metabolism , Oxidative Stress , Vitamin E/metabolism , Animals , Diabetes Mellitus, Experimental/metabolism , Glutathione Disulfide/metabolism , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Lipid Peroxidation , Male , Oxidation-Reduction , Rats , Rats, Wistar , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/analysis
4.
Naunyn Schmiedebergs Arch Pharmacol ; 379(3): 241-51, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18936912

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) is a major complication linked with the metabolic syndrome associated with dyslipidemia, inflammation, and oxidative stress. Impact of type 2 diabetes with hyperlipidemia in NAFLD has to be established, as well as the utility of commonly prescribed anti-diabetic and lipid-lowering agents in improving liver injury markers. Genetic type 2 diabetic Goto-Kakizaki rats were fed with a high-fat diet to test hepatic effects of type 2 diabetes with hyperlipidemia and the effect of atorvastatin and insulin, individually and in combination, in systemic and hepatic inflammatory and oxidative stress markers. High-fat diet aggravated fasting glycemia, systemic and liver lipids, and inflammatory and oxidative stress markers. Individual treatments improved glycemic and lipid profiles, but failed to improve inflammatory markers, whereas insulin was able to reduce liver oxidative stress parameters. Combination of insulin and atorvastatin further improved glycemic and lipid profiles and decreased circulating C-reactive protein levels and liver inflammatory and oxidative stress markers. Insulin and atorvastatin combination leads to better glycaemic and lipid profiles and to better protection against liver inflammation and oxidative stress, giving a superior level of liver protection in type 2 diabetic with hyperlipidemia.


Subject(s)
Anticholesteremic Agents/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Fatty Liver/prevention & control , Heptanoic Acids/therapeutic use , Hyperlipidemias/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Pyrroles/therapeutic use , Administration, Oral , Animals , Anticholesteremic Agents/administration & dosage , Atorvastatin , Biomarkers/blood , Biomarkers/urine , Blood Glucose/analysis , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Type 2/complications , Dietary Fats/administration & dosage , Drug Therapy, Combination , Heptanoic Acids/administration & dosage , Hyperlipidemias/complications , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/blood , Injections, Subcutaneous , Insulin/administration & dosage , Insulin/blood , Insulin Resistance , Lipids/blood , Oxidative Stress/drug effects , Pyrroles/administration & dosage , Rats , Rats, Inbred Strains
5.
Physiol Res ; 58(2): 203-209, 2009.
Article in English | MEDLINE | ID: mdl-18380531

ABSTRACT

Diabetes mellitus is characterized by oxidative stress, which in turn determines endothelial dysfunction. Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring. It has been reported to potentially protect the vasculature through improvements in plasma lipid levels and platelet function. We hypothesized that gliclazide has a beneficial effect on endothelial function in Goto-Kakizaki rats (GK), an animal model of type 2 diabetes fed an atherogenic diet for 4 months. We evaluated the influence of gliclazide on both metabolic and oxidative status and NO-mediated vasodilation. GKAD rats showed increased oxidative stress and impaired endothelium-dependent vasodilation. GKAD rats treated with gliclazide showed increased sensitivity to NO-mediated vasodilation, a significant decrease in fasting glycemia and insulinemia, and a significant decrease in systemic oxidative stress. In conclusion, our results suggest that gliclazide treatment improves NO-mediated vasodilation in diabetic GK rats with dyslipidemia probably due to its antioxidant effects, although we cannot rule out substantial benefits due to a reduction in fasting blood glucose. The availability of a compound that simultaneously decreases hyperglycemia, hyperinsulinemia, and inhibits oxidative stress is a promising therapeutic candidate for the prevention of vascular complications of diabetes.


Subject(s)
Antioxidants/pharmacology , Diabetes Mellitus, Type 2/drug therapy , Diabetic Angiopathies/prevention & control , Dietary Fats/pharmacology , Gliclazide/pharmacology , Hypoglycemic Agents/pharmacology , 8-Hydroxy-2'-Deoxyguanosine , Acetylcholine/pharmacology , Animals , Body Weight , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/urine , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/metabolism , Diabetic Angiopathies/metabolism , Disease Models, Animal , Dyslipidemias/complications , Dyslipidemias/metabolism , Nitric Oxide/metabolism , Oxidative Stress/drug effects , Rats , Rats, Mutant Strains , Rats, Wistar , Vasodilation/drug effects , Vasodilator Agents/pharmacology
6.
Pharmacol Res ; 58(3-4): 208-14, 2008.
Article in English | MEDLINE | ID: mdl-18692137

ABSTRACT

UNLABELLED: Combination therapy recently emerged as a potential therapeutic option in order to improve cardiovascular risk in diabetics, since therapies commonly used in monotherapy failed in significantly optimizing this risk. METHODS: A type 2 diabetes animal model was used to test the effects of a high-fat diet, atorvastatin and insulin (isolated or in association), in glycemic, lipid and inflammatory profiles, oxidative stress markers and cardiac mitochondrial function in ischemia-reperfusion conditions. RESULTS: High-fat diets significantly worsened fasting glycemia and lipid profile; it also increased C-reactive protein (CRP) and oxidative stress and compromised mitochondrial response to ischemia. Insulin decreased fasting glucose and free fatty acid levels and insulin resistance, while increasing HDL-cholesterol, but had no effect in inflammatory markers. Atorvastatin decreased circulating adiponectin levels and did not improve inflammatory markers, although it improved fasting glycemia, glucose tolerance, free fatty acids and HDL-cholesterol. The combined use of atorvastatin and insulin improved several parameters, as did each of the treatments separately. However, treatment association went beyond these results, by decreasing atherogenicity index and circulating CRP levels. Insulin and its association with atorvastatin significantly prevented mitochondrial dysfunction observed in the high-fat diet group, while atorvastatin showed some beneficial effects but in much less extent. CONCLUSIONS: Altogether, these results show that administration of an high-fat diet in a model of type 2 diabetes increases cardiovascular risk and combined use of atorvastatin and insulin provides a superior control of cardiovascular risk markers in diabetic and hyperlipidemic subjects.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Heptanoic Acids/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipidemias/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Pyrroles/therapeutic use , Adiponectin/blood , Animals , Atorvastatin , Biomarkers , Blood Glucose/metabolism , Body Weight/drug effects , Cholesterol/blood , Diabetes Mellitus, Type 2/complications , Dietary Fats/pharmacology , Drug Synergism , Eating/drug effects , Hyperlipidemias/blood , Hyperlipidemias/etiology , In Vitro Techniques , Inflammation/pathology , Insulin Resistance , Lipids/blood , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Mitochondrial Swelling/drug effects , Oxidative Stress/drug effects , Perfusion , Rats , Triglycerides/blood
7.
Br J Pharmacol ; 153(5): 894-906, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17906683

ABSTRACT

BACKGROUND AND PURPOSE: This study was conducted to investigate the effects of alpha-lipoic acid (alpha-LA) on endothelial function in diabetic and high-fat fed animal models and elucidate the potential mechanism underlying the benefits of alpha-LA. EXPERIMENTAL APPROACH: Plasma metabolites reflecting glucose and lipid metabolism, endothelial function, urinary albumin excretion (UAE), plasma and aortic malondialdehyde (MDA) and urinary 8-hydroxydeoxyguanosine (8-OHdG) were assessed in non-diabetic controls (Wistar rats), untreated Goto-Kakizaki (GK) diabetic and high-fat fed GK rats (fed with atherogenic diet only, treated with alpha-LA and treated with vehicle, for 3 months). Vascular eNOS, nitrotyrosine, carbonyl groups and superoxide anion were also assessed in the different groups. KEY RESULTS: alpha-LA and soybean oil significantly reduced both total and non-HDL serum cholesterol and triglycerides induced by atherogenic diet. MDA, carbonyl groups, vascular superoxide and 8-OHdG levels were higher in GK and high-fat fed GK groups and fully reversed with alpha-LA treatment. High-fat fed GK diabetic rats showed significantly reduced endothelial function and increased UAE, effects ameliorated with alpha-LA. This endothelial dysfunction was associated with decreased NO production, decreased expression of eNOS and increased vascular superoxide production and nitrotyrosine expression. CONCLUSIONS AND IMPLICATIONS: alpha-LA restores endothelial function and significantly improves systemic and local oxidative stress in high-fat fed GK diabetic rats. Improved endothelial function due to alpha-LA was at least partially attributed to recoupling of eNOS and increased NO bioavailability and represents a pharmacological approach to prevent major complications associated with type 2 diabetes.


Subject(s)
Antioxidants/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Endothelium, Vascular/drug effects , Thioctic Acid/pharmacology , Aging , Animals , Cholesterol/blood , Diabetes Mellitus, Experimental/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Dietary Fats , Endothelium, Vascular/physiopathology , Gene Expression Regulation, Enzymologic/drug effects , Male , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/drug effects , Nitric Oxide Synthase Type III/metabolism , Oxidative Stress/drug effects , Rats , Rats, Wistar , Soybean Oil/chemistry , Triglycerides/blood
8.
Acta Diabetol ; 44(3): 121-30, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17721750

ABSTRACT

We investigated the effect of sub-chronic soybean oil (SO) treatment on the insulin secretion and fatty acid composition of islets of Langerhans obtained from Goto-Kakizaki (GK), a model of type 2 diabetes, and normal Wistar rats. We observed that soybean-treated Wistar rats present insulin resistance and defective islet insulin secretion when compared with untreated Wistar rats. The decrease in insulin secretion occurred at all concentrations of glucose and arginine tested. Furthermore we observed that soybean-treated normal islets present a significant decrease in two saturated fatty acids, myristic and heneicosanoic acids, and one monounsaturated eicosenoic acid, and the appearance of the monounsaturated erucic acid. Concerning diabetic animals, we observed that soybean-treated diabetic rats, when compared with untreated GK rats, present an increase in plasma non-fasting free fatty acids, an exacerbation of islet insulin secretion impairment in all conditions tested and a significant decrease in the monounsaturated palmitoleic acid. Altogether our results show that SO treatment results in a decrease of insulin secretion and alterations on fatty acid composition in normal and diabetic islets. Furthermore, the impairment of insulin secretion, islet erucic acid and fasting plasma insulin levels are similar in treated normal and untreated diabetic rats, suggesting that SO could have a deleterious effect on beta-cell function and insulin sensitivity.


Subject(s)
Glucose/pharmacology , Insulin/metabolism , Islets of Langerhans/metabolism , Soybean Oil/pharmacology , Animals , Arginine/pharmacology , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/physiopathology , Disease Models, Animal , Fatty Acids/metabolism , Female , Insulin Secretion , Islets of Langerhans/drug effects , Myristic Acid/metabolism , Rats , Rats, Inbred Strains , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...